ArticleScience translational medicine2014
Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy.
Article in Science translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02278315 (Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma), which is not on this map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Comparison of PET Tracers in Recurrent High-Grade Gliomas: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- PEGylated IL2 and tumor-targeted radiotherapy augment CD8Theranostics · 2026Trial
- Small Molecule Drug Conjugate Hybrids of Naphthalene Sulfonamide and Phospholipid Conjugates Are Microtubule-Disrupting Antitumor Agents.Pharmaceutics · 2026Article
- A Phase I Trial of Iopofosine I 131 and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.Cancers · 2026Article
- Enhanced Antitumor Efficacy ofInternational journal of radiation oncology, biology, physics · 2026Article
- Image-Guided Brain Tumor Surgery.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Agents for Fluorescence-Guided Glioblastoma Surgery.Pharmaceutics · 2025Review
- Spatial Control of CAR T Cell Activation Using Tumor-Homing Polymers.Journal of the American Chemical Society · 2025Article
- Cellular and organismal function of choline metabolism.Nature metabolism · 2025Review
- Immunomodulatory effects of alpha vs beta radiopharmaceutical therapy in murine prostate cancer.Frontiers in immunology · 2025Article
- RAS70 peptide targets multiforme glioblastoma by binding to the plasma membrane heat shock protein HSP70.Frontiers in oncology · 2025Article
- Next-generation agents for fluorescence-guided glioblastoma surgery.Bioengineering & translational medicine · 2024Article
- Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy usingJournal for immunotherapy of cancer · 2024Article
- An injectable magnesium-loaded hydrogel releases hydrogen to promote osteoporotic bone repair via ROS scavenging and immunomodulation.Theranostics · 2024Article
- Intraoperative Imaging and Optical Visualization Techniques for Brain Tumor Resection: A Narrative Review.Cancers · 2023Review
- Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC).Molecular cancer research : MCR · 2023Article
- Targeting of Head and Neck Cancer by Radioiodinated CLR1404 in Murine Xenograft Tumor Models with Partial Volume Corrected Theranostic Dosimetry.Cancer biotherapy & radiopharmaceuticals · 2023Article
- Clinical Advances and Perspectives in Targeted Radionuclide Therapy.Pharmaceutics · 2023Review
- Effect of Polar Head Group Modifications on the Tumor Retention of Phospholipid Ether Analogs: Role of the Quaternary Nitrogen.Pharmaceutics · 2023Article
- Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination.Journal for immunotherapy of cancer · 2023Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Many solid tumors contain an overabundance of phospholipid ethers relative to normal cells. Capitalizing on this difference, we created cancer-targeted alkylphosphocholine (APC) analogs through structure-activity analyses. Depending on the iodine isotope used, radioiodinated APC analog CLR1404 was used as either a positron emission tomography (PET) imaging ((124)I) or molecular radiotherapeutic ((131)I) agent. CLR1404 analogs displayed prolonged tumor-selective retention in 55 in vivo rodent and human cancer and cancer stem cell models. (131)I-CLR1404 also displayed efficacy (tumor growth suppression and survival extension) in a wide range of human tumor xenograft models. Human PET/CT (computed tomography) and SPECT (single-photon emission computed tomography)/CT imaging in advanced-cancer patients with (124)I-CLR1404 or (131)I-CLR1404, respectively, demonstrated selective uptake and prolonged retention in both primary and metastatic malignant tumors. Combined application of these chemically identical APC-based radioisosteres will enable personalized dual modality cancer therapy of using molecular (124)I-CLR1404 tumor imaging for planning (131)I-CLR1404 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.